FindTrial
Sign In

Temozolomide SUN 5 mg hard capsules

DRUG7 trials

Sponsors

Debiopharm International S.A., Bristol-Myers Squibb Services Unlimited Company, Nerviano Medical Sciences S.r.l., Pfizer Inc., Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Conditions

Diffuse Midline GliomaGlioblastomaH3K27-alteredIDH1-mutant GliomaIDH2-mutant GliomaPan tumorRecurrent Glioblastomarecurrent or refractory neuroblastoma

Phase 1

A phase 1/2 open-label study of Debio 0123 in combination with temozolomide in adult participants with recurrent or progressive glioblastoma and of Debio 0123 in combination with temozolomide and radiotherapy in adult participants with newly diagnosed glioblastoma
RecruitingCTIS2022-502156-31-00
Debiopharm International S.A.Glioblastoma
Start: 2023-05-26Target: 55Updated: 2025-11-03
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma
SuspendedCTIS2023-508318-41-00
Nerviano Medical Sciences S.r.l.Recurrent Glioblastoma
Start: 2021-09-30Target: 36Updated: 2024-11-13
A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
CompletedCTIS2024-511975-14-00
Pfizer Inc.recurrent or refractory neuroblastoma, recurrent/refractory Ewing sarcoma
Start: 2022-05-26End: 2025-08-06Target: 29Updated: 2025-09-08
A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma
Active, not recruitingCTIS2024-513738-39-00
Institut De Recherches Internationales Servier IRISIDH1-mutant Glioma, IDH2-mutant Glioma
Start: 2025-03-18Target: 17Updated: 2025-12-18
FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide – an exploratory pilot and feasibility trial
Not yet recruitingCTIS2025-520814-78-00
Universitair Medisch Centrum UtrechtDiffuse Midline Glioma, H3K27-altered
Target: 20Updated: 2026-03-23

Phase 2

Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Bristol-Myers Squibb Services Unlimited CompanyPan tumor
Start: 2020-05-05Target: 307Updated: 2026-01-19
Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II Study (Combi G-Vax)
RecruitingCTIS2024-512493-98-00
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.Glioblastoma
Start: 2021-03-25Target: 28Updated: 2024-07-15